| Species |
Human |
| Protein Construction |
HLA-A*24:02&B2M&Survivin 2B (AYACNTSTL) Monomer[Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M) and AYACNTSTL peptide]
Accession # AAA59600.1(HLA-A*24:02)&P61769(B2M)&AYACNTSTL |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
50.20 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 53-63 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Survivin-2B, a known splice variant of survivin, has been reported to promote cell death in some cancer cells, although it keeps prosurvival function in others.survivin-2B promoted autophagy and further regulated cell death by accumulating and stabilizing IKK alpha in the nucleus. |
| Synonyms |
svn-2B; Survivin-2B; svn 2B |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
